DexCom (DXCM) Stock Buyback History
TTM buyback yield 2.22% · Shareholder yield (TTM) 2.22%.
DXCM
TTM buyback yield
2.22%
Shareholder yield (TTM)
2.22%
5Y share count change
4.0%
TTM buyback spend
$535.80M
SBC coverage (TTM)
3.18x
YoY change in spend
-33.3%
5Y CAGR of spend
N/A
Peak year (2024)
$750.00M
Cumulative spend
$2.60B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- DexCom (DXCM) repurchased about $535.80M of stock over the trailing twelve months.
- Diluted share count is up 4.0% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 3.18× — repurchases more than cover SBC dilution.
- TTM repurchases used about 37% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $500.00M | $159.60M | $340.40M | 0.41B | -1.7% | 1.95% |
| 2024 | $750.00M | $170.40M | $579.60M | 0.41B | -3.0% | 2.42% |
| 2023 | $688.70M | $150.80M | $537.90M | 0.43B | -0.5% | 1.44% |
| 2022 | $557.70M | $126.50M | $431.20M | 0.43B | -0.3% | 1.27% |
| 2021 | $0.00 | $113.40M | −$113.40M | 0.43B | 9.9% | — |
| 2020 | $0.00 | $119.40M | −$119.40M | 0.39B | 5.6% | — |
| 2019 | $0.00 | $102.70M | −$102.70M | 0.37B | 4.6% | — |
| 2018 | $100.00M | $101.90M | −$1.90M | 0.35B | 2.2% | 0.94% |
| 2017 | $0.00 | $106.20M | −$106.20M | 0.35B | 3.2% | — |
| 2016 | $0.00 | $110.80M | −$110.80M | 0.33B | 4.8% | — |
| 2015 | $0.00 | $82.70M | −$82.70M | 0.32B | 6.1% | — |
| 2014 | $0.00 | $50.00M | −$50.00M | 0.30B | 5.8% | — |
| 2013 | $0.00 | $24.60M | −$24.60M | 0.28B | 3.5% | — |
| 2012 | $0.00 | $18.40M | −$18.40M | 0.27B | 4.7% | — |
| 2011 | $0.00 | $13.51M | −$13.51M | 0.26B | 15.3% | — |
| 2010 | $0.00 | $9.44M | −$9.44M | 0.23B | 28.3% | — |
| 2009 | $0.00 | $8.37M | −$8.37M | 0.18B | 50.4% | — |
| 2008 | $0.00 | $7.68M | −$7.68M | 0.12B | 4.1% | — |
| 2007 | $2.73M | $6.12M | −$3.39M | 0.11B | 4.0% | 1.09% |
| 2006 | $0.00 | $5.85B | −$5.85B | 0.11B | 43.8% | — |
| 2005 | $0.00 | $1.67B | −$1.67B | 0.08B | 728.7% | — |
| 2004 | $0.00 | $0.00 | $0.00 | 0.01B | 5.3% | — |
| 2003 | $0.00 | $0.00 | $0.00 | 0.01B | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for DexCom (DXCM) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for DexCom (DXCM)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for DexCom (DXCM)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $500.00M | -33.3% | -$250.00M | ||
| 2024 | $750.00M | +8.9% | +$61.30M | ||
| 2023 | $688.70M | +23.5% | +$131.00M | ||
| 2022 | $557.70M | — | +$557.70M | ||
| 2021 | $0 | — | $0 | ||
| 2020 | $0 | — | $0 | ||
| 2019 | $0 | -100.0% | -$100.00M | ||
| 2018 | $100.00M | — | +$100.00M | ||
| 2017 | $0 | — | $0 | ||
| 2016 | $0 | — | $0 | ||
| 2015 | $0 | — | $0 | ||
| 2014 | $0 | — | $0 | ||
| 2013 | $0 | — | $0 | ||
| 2012 | $0 | — | $0 | ||
| 2011 | $0 | — | $0 | ||
| 2010 | $0 | — | $0 | ||
| 2009 | $0 | — | $0 | ||
| 2008 | $0 | -100.0% | -$2.73M | ||
| 2007 | $2.73M | — | +$2.73M | ||
| 2006 | $0 | — | $0 | ||
| 2005 | $0 | — | $0 | ||
| 2004 | $0 | — | $0 | ||
| 2003 | $0 | — | — |
DexCom (DXCM) most recent annual buyback spend stands at $500.00M (2025) – plunged 33.3% year-over-year.
DexCom buyback spend peaked at $750.00M in 2024; the latest annual figure is $500.00M in 2025 (33.3% below peak).
$750.00M stands as the all-time-high annual buyback spend, posted in 2024, against a low of $0 during 2003.
Among 8 Healthcare peers, DexCom (DXCM) ranks 8th; the peer median for buyback spend is $2.75B.
DexCom Buyback Spend 2025: $500.00M
DexCom buyback spend in 2025 was $500.00M, plunged 33.3% below 2024.
DexCom Buyback Spend 2024: $750.00M
DexCom buyback spend in 2024 was $750.00M, grew 8.9% from 2023. This figure represents the highest annual value in the available history.
DexCom Buyback Spend 2023: $688.70M
DexCom buyback spend in 2023 was $688.70M, grew 23.5% from 2022.
DexCom Buyback Spend 2022: $557.70M
DexCom buyback spend in 2022 was $557.70M.
DexCom Buyback Spend 2021: $0
DexCom buyback spend in 2021 was $0.
See more financial history for DexCom (DXCM).
Sector peers by buyback spend
Companies in the same sector as DexCom, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 3.18×.
Capital allocation mix
How DexCom splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $1.43B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from DexCom's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does DexCom buy back its own stock?
Yes, DexCom (DXCM) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does DexCom spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $535.80M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is DexCom's buyback yield?
TTM buyback yield is about 2.22% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is DexCom's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 2.22% combined (TTM-based where available).
Is DexCom diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has DexCom's share count changed?
Diluted weighted average shares changed by about 4.0% over roughly five fiscal years (annual income statement data).
What is DexCom's buyback spend?
Latest reported buyback spend for DexCom (DXCM) is $535.80M (period ending March 31, 2026).
How has DexCom buyback spend changed year-over-year?
DexCom (DXCM) buyback spend changed -33.3% year-over-year on the latest annual filing.
When did DexCom buyback spend hit its highest annual value?
DexCom buyback spend reached its highest annual value of $750.00M in 2024.
What was DexCom buyback spend in 2024?
DexCom (DXCM) buyback spend in 2024 was $750.00M.
What was DexCom buyback spend in 2025?
DexCom (DXCM) buyback spend in 2025 was $500.00M.
Explore more
DXCM Overview
Company profile, financial tools, and key metrics
DXCM Revenue Counter
Earns $152.77 every second. See per minute, hour, and day.
DXCM Earnings Counter
Earns $29.50 per second net profit. See per minute, hour, and day.
DXCM Economic Scale
Exceeds Liberia's GDP. Compare with world economies.
DXCM What If Invested
What if you had invested $1,000? See historical returns from any date.
DXCM How It Makes Money
Discover visual breakdown of $4.82B in revenue — where it comes from and where it goes.
DXCM Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DXCM Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DXCM Daily Price Character
Explosive · 49.4% historical win rate (green days). Streaks & record days.
DXCM Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.
DXCM Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.